Summary
Vertex Pharmaceuticals Inc. (VRTX) announced a significant change to its board of directors with the appointment of Michel Lagarde, effective October 5, 2023. Mr. Lagarde brings extensive experience from leadership roles at Thermo Fisher Scientific, including his current position as Executive Vice President and Chief Operating Officer. His background also includes experience in private equity within the healthcare sector, suggesting a valuable addition to Vertex's strategic oversight. This appointment increases the size of the Board from nine to ten members. Mr. Lagarde's compensation for joining the board includes a substantial $400,000 restricted stock unit award, which is scheduled to vest in October 2024. This signals a commitment to aligning director interests with shareholder value. The filing also confirms no related-party transactions or specific appointment understandings requiring further disclosure.
Key Highlights
- 1Michel Lagarde appointed as a new member of the Board of Directors, effective October 5, 2023.
- 2Board size increased from nine to ten members.
- 3Mr. Lagarde's extensive experience includes his current role as Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific.
- 4His prior roles at Thermo Fisher and Patheon N.V., along with his background in private equity (JLL Partners), provide valuable industry and financial expertise.
- 5Mr. Lagarde received a $400,000 restricted stock unit award upon appointment, vesting in October 2024.
- 6No reportable transactions between the Company and Mr. Lagarde under Item 404(a) of Regulation S-K.
- 7No arrangements or understandings exist for Mr. Lagarde's appointment beyond standard board procedures.